NIH-funded research R01 grant

Mechanical cues to boost stem cell therapy for graft-versus-host disease

Official title: Mechanical programming to enhance the immunosuppressive function of mesenchymal stem cells for the treatment of graft-versus-host disease

Funded at Johns Hopkins University · NIH-11298671 · Data updated 2026-11-12

Researchers are testing a way to make stem cells more powerful at calming immune reactions in people with graft-versus-host disease.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionJohns Hopkins University
NIH-funded
Lab location1 site (Baltimore, United States)
Project startJuly 1, 2026
Project endJune 30, 2030
Funding year2026
Award (this year)$379,509
NIH project number1R01HL179424-01A1
Project IDNIH-11298671 on NIH RePORTER

Who could benefit from this research

Could help

Patients with acute graft-versus-host disease who are candidates for MSC-based therapy or related clinical trials.

Less likely to help

Patients not eligible for MSC-based therapy or not participating in GVHD-related studies may not benefit.

What this research studies

Mesenchymal stem/stromal cells (MSCs) might quiet overactive immune systems, which could help treat graft-versus-host disease. This project looks at how the physical environment around MSCs—specifically how stiff and viscoelastic the surroundings are—affects their ability to suppress immune responses. By tuning these mechanical cues in the lab, scientists aim to produce MSCs with stronger therapeutic effects before they are used in patients. The study uses advanced hydrogel systems to mimic tissue mechanics and to identify production conditions that maximize MSC potency. If successful, this approach could lead to more reliable MSC-based therapies for GVHD patients.

Why it matters

Potential benefit: If successful, patients with GVHD could receive MSC treatments that work more consistently and effectively.

How similar studies have gone: Previous research suggests that mechanical cues can influence MSC function, with ongoing work to translate this into more potent cell therapies.

Where this research is happening

  • Johns Hopkins University
    Baltimore, United States
    Active

Researchers

  • Principal investigator: Gu, Luo — Johns Hopkins University
  • Study coordinator: Gu, Luo

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.